Acute Intermittent Porphyria Clinical Trial
Official title:
A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)
The purpose of this study is to evaluate the safety and tolerability of givosiran (ALN-AS1) in AIP patients as well as to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of ALN-AS1 in AIP patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02922413 -
Panhematin for Prevention of Acute Attacks of Porphyria
|
Phase 2 | |
| Completed |
NCT02949830 -
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
|
Phase 1/Phase 2 | |
| Completed |
NCT02943213 -
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
|
Phase 1 | |
| Completed |
NCT02082860 -
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
|
Phase 1 | |
| Completed |
NCT03338816 -
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
|
Phase 3 | |
| Completed |
NCT00418795 -
Porphozym in the Treatment of Acute Attacks in AIP
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT01617642 -
Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
|
||
| Completed |
NCT02076763 -
Observational Study of Acute Intermittent Porphyria Patients
|
N/A | |
| Active, not recruiting |
NCT02935400 -
Acute Porphyria Biomarkers for Disease Activity
|